Carbocisteine in vivo reduces circulating miR-21 and IL-8 in exacerbated COPD patients
M. Ferraro (Pa, Italy), S. Di Vincenzo (Pa, Italy), S. Bucchieri (Pa, Italy), P. Dino (Pa, Italy), M. Leto Barone (Pa, Italy), S. Gangemi (Me, Italy), F. Saibene (Mi, Italy), L. Lanata (Mi, Italy), E. Pace (Pa, Italy)
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Session: COPD clinical trials: inhaled and oral therapies
Session type: Thematic Poster
Number: 2487
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Ferraro (Pa, Italy), S. Di Vincenzo (Pa, Italy), S. Bucchieri (Pa, Italy), P. Dino (Pa, Italy), M. Leto Barone (Pa, Italy), S. Gangemi (Me, Italy), F. Saibene (Mi, Italy), L. Lanata (Mi, Italy), E. Pace (Pa, Italy). Carbocisteine in vivo reduces circulating miR-21 and IL-8 in exacerbated COPD patients. 2487
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: